Vertex Enters Into Agreement to Acquire Alpine Immune Sciences
Apr 10, 2024 · Under the terms of the merger agreement, Vertex will acquire Alpine for $65 per share in cash, for a total equity value of approximately $4.9 billion, or approximately $4.6 …
Vertex to Present Phase 3 Data Highlighting Suzetrigine’s Potential …
Oct 18, 2024 · Vertex’s approach is to selectively inhibit NaV1.8 using small molecules with the objective of creating a new class of pain signal inhibitors that have the potential to provide …
Vertex Reports Third Quarter 2024 Financial Results | Vertex ...
Sep 30, 2024 · BOSTON--(BUSINESS WIRE)--Nov. 4, 2024-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the third quarter …
Vertex Announces US FDA Approval of ALYFTREK™, a Once-Daily …
Dec 20, 2024 · Vertex Announces US FDA Approval of ALYFTREK™, a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis - ALYFTREK ™ is approved for patients …
Press Release - Vertex Pharmaceuticals Newsroom
Jul 30, 2024 · BOSTON--(BUSINESS WIRE)--Jul. 30, 2024-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration …
Vertex and TreeFrog Therapeutics Announce Licensing Agreement …
Apr 23, 2024 · TreeFrog and Vertex will collaborate to scale-up TreeFrog’s process to produce and amplify cells for Vertex’s T1D therapies. TreeFrog’s proprietary technology platform, C …
Press Release - Vertex Pharmaceuticals Newsroom
Mar 9, 2023 · Vertex’s first clinical investigational program in T1D, VX-880, is a stem cell-derived, fully differentiated, insulin-producing islet cell replacement therapy used in combination with …
Vertex Announces Publication in New England Journal of Medicine …
Mar 16, 2023 · BOSTON --(BUSINESS WIRE)--Mar. 16, 2023-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced publication in the New England Journal of …
Vertex to Participate in Upcoming June Investor Conferences
May 22, 2024 · Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has approved …
Vertex to Announce First Quarter 2023 Financial Results on May 1 ...
Apr 10, 2023 · BOSTON--(BUSINESS WIRE)--Apr. 10, 2023-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2023 financial results on Monday, May …
- Some results have been removed